Meeting
2021 ASCO Annual Meeting
Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer in the ECOG-ACRIN 5103 trial.
Authors
Joseph A. Sparano
Montefiore Medical Center/Albert Einstein College of Medicine/Albert Einstein Cancer Center, Bronx, NY
Joseph A. Sparano , Anne M. O'Neill , Noah Graham , Donald W. Northfelt , Chau T. Dang , Antonio C. Wolff , George W. Sledge Jr., Kathy Miller
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT00433511
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 520)
DOI
10.1200/JCO.2021.39.15_suppl.520
Abstract #
520
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Dynamics of circulating cytokines and chemokines during and after tumor-infiltrating lymphocyte cell therapy with lifileucel in advanced melanoma patients.
First Author: Rongsu Qi
Poster
2018 ASCO Annual Meeting
Immune profiling of pre- and post-treatment breast cancer tissues from the S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamide.
First Author: Xiaotong Li
Poster
2018 ASCO Annual Meeting
Symptom burden and employment status in breast cancer (BC) survivors.
First Author: Ines Maria Vaz Duarte Luis
Poster
2014 ASCO Annual Meeting
Outcomes of 3-weekly doxorubicin and cyclophosphamide followed by paclitaxel (AC/T) in a randomized trial (RCT) compared to a case-control matched British Columbia (BC) breast cancer population.
First Author: Sheridan Marie Wilson